Showing 2001-2010 of 2192 results for "".
- Clinical Trials of Vidofludimus for Relapsing and Progressive Multiple Sclerosis Get Green Lighthttps://practicalneurology.com/news/clinical-trials-of-vidofludimus-for-relapsing-and-progressive-multiple-sclerosis-get-green-light/2469628/The Food and Drug Administration (FDA) cleared phase 3 ENSURE (NCT identifier not yet available) and phase 2 CALLIPER (NCT identifier not yet available) clinical trials of vidofludimus calcium (VFC)(IMU-83
- FDA Grants Orphan Drug Exclusivity for Mixed Salts Oxybate for Cataplexy or Excessive Daytime Sleepinesshttps://practicalneurology.com/news/fda-grants-orphan-drug-exclusivity-for-mixed-salts-oxybate-for-cataplexy-or-excessive-daytime-sleepiness/2469624/The Food and Drug Administration has granted 7 years of Orphan Drug Exclusivity for mixed salts oxybate (Xywav; Jazz Pharmaceuticals, Philadelphia, PA) for the treatment of cataplexy or excessive daytime sleepiness (EDS) caused by narcolepsy in individuals age 7 years or more. FDA
- Ublituximab Reduced Annualized Relapse Rate and Disability Progression in Multiple Sclerosishttps://practicalneurology.com/news/ublituximab-reduced-annualized-relapse-rate-and-disability-progression-in-multiple-sclerosis/2469621/In the phase 3 ULTIMATE trials (NCT03277261 and NCT03277248), ublituximab (UTX)(TG Therapeutics, New York, NY) decreased (ARR) and disability progression of relapsing multiple
- Nusinersen Treatment of Spinal Muscular Atrophy Provides Continued Motor Development and Studies Will Evaluate a Higher Dosehttps://practicalneurology.com/news/nusinersen-treatment-of-spinal-muscular-atrophy-provides-continued-motor-development-and-studies-will-evaluate-a-higher-dose/2469614/Continued development and studies of nusinersen (Spinraza; Biogen, Cambridge, MA), the first of several treatments for spinal muscular atrophy (SMA) developed in just the last 5 years, show sustained survival and improvement in motor function. Studies also suggest a higher dose may be more effect
- Rimegepant Now Approved for Both Acute and Preventive Migraine Treatmenthttps://practicalneurology.com/news/rimegepant-now-approved-for-both-acute-and-preventive-migraine-treatment/2469603/The FDA has approved rimegepant (Nurtec; Biohaven Pharmaceuticals, New Haven, CT) for the additional indication of preventive treatment of migraine. The approval for preventative migraine treatment makes rimegepant the first drug approved to treat acute migraine attacks and help prevent future mi
- Diagnostic Kit Provides Accurate Spinal Muscular Atrophy Copy Number and Diagnosishttps://practicalneurology.com/news/diagnostic-kit-provides-accurate-spinal-muscular-atrophy-copy-number-and-diagnosis/2469589/A study published in The Journal of Molecular Diagnostics, showed an in vitro diagnostic kit (AmplideX Kit; Bio-Techne Corporation, Minneapolis, MN) has accuracy for timely results of carrier identification or diagnosis of spinal muscular atrophy (SMA). In the study, the single-tu
- Increased Risk of Dementia Correlates With Decreased Kidney Functionhttps://practicalneurology.com/news/increased-risk-of-dementia-correlates-with-decreased-kidney-function/2469588/In a registry-based study published in Neurology, individuals with reduced kidney function had increased risk of dementia development. In the study, there were cases of dementia per 1,000 person-years in individuals with a normal kidney filtration rate of 90 to 104 mL per minute and with severe k
- Soticlestat Reduces Seizure Frequency in Developmental and Epileptic Encephalopathieshttps://practicalneurology.com/news/soticlestat-reduces-seizure-frequency-in-developmental-and-epileptic-encephalopathies/2469584/Long-term treatment with soticlestat (OV935/TAK935; Ovid Therapeutics, New York, NY) in individuals with developmental and epileptic encephalopathies (DEE) reduced seizure frequency in the ENDYMION open-label extension study (
- SAGE Cognitive Screening Tool Increased Detection of Cognitive Declinehttps://practicalneurology.com/news/sage-cognitive-screening-tool-increased-detection-of-cognitive-decline/2469582/In a study presented at the American Academy of Neurology Virtual Annual Meeting April 17-22, use of a self-administered gerocognitive examination (SAGE) combined with an informant report of significant cognitive decline over a year increased detection of cognitive impairment 15-fold. SAGE is a w
- Vidofludimus Calcium a Selective T- and B-Cell Reduced Multiple Sclerosis Disease Activityhttps://practicalneurology.com/news/vidofludimus-calcium-a-selective-t-and-b-cell-reduced-multiple-sclerosis-disease-activity/2469566/In the phase 2 EMPhASIS trial (NCT03846219) vidofludimus calcium (VFC)(IMU-838; Immunic, New York, NY) reduced new combined unique active (CUA) MRI lesions in individuals with multiple sclerosis (MS). CUA is a measure that counts uniqu